The government has initiated 950 enforcement actions against pharmaceutical companies since December 2022. These actions aim to improve the quality of locally made medicines and prevent spurious drug sales. More than 1,100 cough syrup manufacturers are facing intense audits due to quality concerns. Drug manufacturing premises are inspected periodically to verify compliance with good manufacturing practices. Risk-based inspections are now prioritized based on a company's risk profile.